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Abstract
Precision oncology, the genetic sequencing of tumors to identify druggable targets,
has emerged as the standard of care in the treatment of many cancers. Nonetheless,
due to the pace of therapy development and variability in patient information,
designing effective protocols for individual treatment assignment in a sample-
efficient way remains a major challenge. One promising approach to this problem
is to frame precision oncology treatment as a contextual bandit problem and to
apply sequential decision-making algorithms designed to minimize regret in this
setting. However, a clear prerequisite for considering this methodology in high-
stakes clinical decisions is careful benchmarking to understand realistic costs and
benefits. Here, we propose a benchmark dataset to evaluate contextual bandit
algorithms based on real in vitro drug response of approximately 900 cancer cell
lines. Specifically, we curated a dataset of complete treatment responses for a
subset of 7 treatments from prior in vitro studies. This allows us to compute the
regret of proposed decision policies using biologically plausible counterfactuals.
We ran a suite of Bayesian bandit algorithms on our benchmark, and found that the
methods accumulate less regret over a sequence of treatment assignment tasks than
a rule-based baseline derived from current clinical practice. This effect was more
pronounced when genomic information was included as context. We expect this
work to be a starting point for evaluation of both the unique structural requirements
and ethical implications for real-world testing of bandit based clinical decision
support.
∗Additional affiliation of Niklas Rindtorff, Nisarg Patel and MingYu Lu: Department of Biomedical infor-
matics, Harvard Medical School, 10 Shattuck Street Boston, MA 02115
33rd Conference on Neural Information Processing Systems (NeurIPS 2019), Vancouver, Canada.
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1 Introduction
Precision oncology, the genetic sequencing of tumors to identify druggable targets, has quickly
progressed as the standard of care in the treatment of many cancers [7]. Here, targeted treatments
show therapeutic activity in subsets of patients defined by tumor-specific genetic alterations, such as
imatinib for chronic myelogenous leukemia. [1] However, assigning patients to adequate treatments
remains challenging. Current practice applies published and approved therapeutic protocols that
consider the patient’s clinical characteristics, including the presence of (most often one) particular
genetic mutation, to choose a therapeutic. For example, based on the presence of a single genetic
variant, such as a BRAF V600E mutation (a gene involved in cell growth), a treatment decision
can be made [2]. However, this limits the ability to make high-confidence clinical decisions in a
real-world scenario with a large number of both observable genetic data and treatment options to
choose from. The implications for the practice of precision oncology are (I) a high selectivity: only
4.9% of oncology patients are eligible for genome-targeted therapies with robust clinical evidence
[9], and subsequently (II) high compassionate use: the majority of oncology patients are left with
limited treatment options outside of existing therapeutic protocols, of which off-label use does not
contribute systematically to the development of new clinical evidence.
Given the nature of precision oncology, treatment assignment can be modeled as a contextual bandit
problem with a patient’s information informing the choice of treatment. In contrast to supervised
learning on the one end and reinforcement learning on the other end, contextual bandit problems,
especially when based on Thompson sampling, are a well-suited method for this task as it allow
agents to explore new treatment options while ensuring that every action has a non-zero chance of
being optimal [10]. Put differently, Thompson sampling based agents would never make choices
for a patient that are certainly non-optimal in order to improve decision making at a later time
point, something that can not be excluded for more most full reinforcement learning algorithms.
While contextual bandit applications in oncology have been previously proposed [3, 8], there are no
established benchmarks to evaluate different algorithms, objectives, and state representations, due to
a lack of biologically interpretable and complete observations of drug response in cancer. This is
especially relevant as major ethical questions of how to balance the competing directives of individual
utility and population utility remain.
Here we propose a benchmark for contextual bandits in precision oncology based on real in vitro
drug response of approximately 900 cancer cell lines [6]. For each cell line, mutation, copy number
variation, and gene expression data is available to represent the sample’s state. After defining rewards
based on treatment response, we used all available algorithms implemented in the Bayesian bandit
showdown project [5, 10] to subsequently choose the best treatments for randomly selected cell
lines. In addition, we defined a rule-based agent based on a set of current evidence-based therapeutic
protocols to evaluate bandit performance and to include prior knowledge into the available state
information during selected experiments.
2 Methods
2.1 Benchmark Construction
We derived all molecular and drug sensitivity data from the Genomics of Drug Sensitivity in Cancer
database, a public research repository described by Iorio et al [6] and available at https://www.
cancerrxgene.org. In a first pre-processing step we focused on a subset of 7 drugs that are currently
used in clinical practice. We log transformed the IC50 values and normalized them relative to
the median ln(IC50) across cell-lines for each drug. We used the resulting score to quantify drug
response and calculate response-based rewards (Figure 1A).
In order to reduce the dimensionality of the state representation, we reduced 18523 cell-line specific
features including scaled gene expression data, and binarized mutation and copy-number variant
information into 20 dimensions by uniform manifold approximation and projection (UMAP) using
default parameters. UMAP projected features recovered tissue types (Figure 1B) while not directly
recovering overall drug sensitivities (Figure 1C).
Next we manually curated therapeutic protocols based on current clinical evidence, established and
recent databases, as well as trial protocols with selected simplifications: (I) we excluded any protocols
involving combination treatments, (II) we excluded any protocols that are based on the presence of
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Figure 1: Benchmark Construction. A Drug vulnerability data for 896 cell lines and 5 drugs.
Blue color corresponds to high drug sensitivity. Only 5 of 7 treatment choices are shown. B 20-
dimensional embedding of genomic information for all cancer cell lines included in the study. The
first two dimensions of the UMAP embedding recovered tissue type differences between cancer cell
lines. C The first two dimensions of the UMAP embedding did not completely recover differences in
drug sensitivity
Figure 2: Contextual bandit experimental results. A Rules derived from current therapeutic protocols
which are used by the refernce "Clinical Guideline" agent. B Overview of the experimental setup.
Both state representation and reward function are varied between experiments. C Overview of model
performance across reward metrics and state definitions. Dashed line represents the performance of
the rule-based agent. A higher score indicates lower regret and better performance. D Agent activity
over time for different posterior distribution approximations. In this example, state was represented
by both genetic information and clinical guidelines. In this instance, RMS was the most successful
model.
oncogenic gene-fusions as they were not included in our dataset, (III) in analogy to a basket trials, we
did not include tissue type restrictions into any protocols. Cell lines that did not qualify for any of the
curated treatments were assigned to be treated with Cisplatin, an established chemotherapeutic used,
among others, for treatment of cancers of unknown progeny (Figure 2A).
2.2 Contextual Bandit Formulation
We followed the definition of the contextual bandit problem as described in [10]. The algorithm
assigns treatments to units sequentially. At a time t = 1, · · · , n the algorithm takes as input a context
corresponding to the next unit Xt (e.g., a cell line’s projected genetic data). The algorithm selects one
of k actions at (e.g., one of 7 available treatments). A reward rt = rt(Xt, at) is then generated and
returned. At the end, the cumulative reward for the algorithm is defined as r =
∑n
t=1 r
t. The goal is
to maximize cumulative reward, and thus minimize the cumulative regret, defined as RA = E[r−r∗],
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where r∗ is the cumulative reward of the optimal policy (i.e., the policy that always selects the ideal
treatment given the context).
Similar to the study in [10], we exclusively examined the performance of decision making via
Thompson sampling. In each round of Thompson Sampling, parameters, θt, are sampled from the
posterior distribution pit−1 given all previous observations. Using these parameters and the current
context Xt, an action at is chosen to optimize the expected regret E[rt|θt, at, xt] according to an
internal model.
In this study, we examined the effect of (I) different state representations (II) different reward functions
and (III) different posterior distribution approximations [10] on performance. We evaluated three
different state representations by including only genetic features, only rule-based recommendations
or both datatypes in the state. Thus, in total, the state was represented by up to 27 features (20 UMAP
+ 7 recommendations). Further we defined three different reward metrics:
• subtract the lowest drug response score (the strongest response) from the response score of
the selected drug.
• rank the drugs by drug response score in ascending order. The best drug will be ranked 7,
while the least active drug will be ranked 1.
• for each drug, we map its response score to its distribution over cell lines and use the
percentile as reward.
For posterior approximation, we consider all of the Bayesian bandit algorithms included in [10]
with default parameters. These included uniform sampling, Bayesian linear regression, Gaussian
Processes, stochastic variational inference, and several neural-network based approximations. A full
listing of methods and their hyperparameters are included in the appendix.
For each state representation, reward function and all posterior approximators, we ran 100 epochs
with 512 as the batch size for deep Bayesian network training to obtain the final results. We repeated
each experiment with 5 independent random seeds, thus generating 5 random patient sequences to go
through. We did not define a separate validation dataset to measure agent performance, as commonly
done in methods such as cross-validation, because the UMAP representation was learned on the
complete dataset, leading to an overestimation of agent performance.
All experiments were run in python 3.6 using modified code from the Deep Bayesian Bandits Li-
brary, including an additional rule-based "Clinical Guideline" agent that followed current therapeutic
protocols and a logging function to export an agent’s actions over all experiment steps.
3 Results
Overall, our results suggest that contextual bandit algorithms show promise in the precision oncology
setting. In our experiments, contextual bandits methods were able to leverage genomic information
to consistently achieve substantially lower regret than both uniform random allocation and rule-based
clinical guidelines 2B. This main result is shown in Figure 2C with an exemplary plot visualising
agent activity 2D. Specifically, in a baseline experiment where each algorithm was only given the
information needed to implement clinical guidelines, all agents out-performed uniform random
allocation, and had comparable performance to the rule-based reference agent (bottom row). This was
to be expected, as clinical guidelines have already been tuned to take advantage of this information.
However, when genomic information was available, most of the contextual bandit algorithms were
able to improve on the rule-based protocol significantly (top and middle rows). Providing both
genomic information and guideline input in the state information did not further improve model
performance in most cases (top row vs middle row).
These results were generally robust across reward definitions (columns), although the percentile-based
reward showed the weakest results. Of note, three Neural Network based algorithms, bootstrapped-,
greedy and Dropout, consistently scored higher rewards compared to linear methods or Gaussian
Processes.
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4 Discussion
In summary, we state that genomics based assignment mechanisms in precision oncology programs
can be framed as a contextual bandit problem. When provided with a representation of genomic
information, contextual bandit agents can outperform simplified abstractions of current clinical
standards based on in vitro drug response data. Among the most successful agents were bootstrapped
or dropout-based dense neural networks.
This study has several limitations including: (I) In vitro drug response data of cancer models has
limited transferability into a clinical context although recovering a considerable portion of clinically
established genetic predictors of drug response [6], (II) The response scores are on average lower
in treatments vs. reference agents, (III) We reduced the dimensionality of available genomic data
without dedicated learning of a shared multi-omics embedding, for example as described in [11] (IV)
Cisplatin is a limited reference treatment for all considered cancer types.
We decided to reduce the dimensionality of the available feature space in order to reduce model
complexity and increase training efficiency. We chose UMAP for this purpose as it recovers both
global- and local structure of the dataset. As mentioned before, we believe that this dataset does
not only offer a benchmark for machine learning based treatment assignment for cancer, but also
action-oriented mulitomic feature representation of this disease.
In the future, we plan to address the limitations above and validate our findings in alternative in
vitro and in vivo drug response datasets [4], which were measured by perturbing cancer cell lines,
patient-derived organoids or xenografts. Clinical outcome data, although valuable, does not lend
itself directly for benchmarking, as not all available treatments have been observed for every patient
and thus no ideal policy beyond the standard of care is known. Nevertheless, we plan to validate
out finding by analyzing agent behaviour for action-patterns that correspond to current clinical best
practices. In addition, we plan to measure the impact of certain genomic information types on model
performance, for example by using only the available information provided by current genetic testing
services.
We would like to stimulate an open discussion about the limitations and potential benefits of bandit-
guided treatment assignments in precision oncology programs to minimize collective treatment
regret.
5 Code and Data availability
All code and data can be accessed in this repository or the following directory.
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A Full Listing of Bayesian Bandit Algorithms
Here we list the full suite of Bayesian bandit algorithms that we evaluated with our benchmark.
• Uniform Sampling (Takes each action at random with equal probability)
• Bayesian linear (Noise prior a0 = 6, b0 = 6. Ridge prior λ = 0.25)
• Neural Linear (Noise prior a0 = 3, b0 = 3. Ridge prior λ = 0.25. Based on RMS2 net)
• Neural Greedy (Greedy NN approach with fixed learning rate (γ = 0.01))
• Dropout (Dropout with probability p = 0.8. Based on RMS3 net)
• Parameter-Noise (Initial noise σ = 0.01, and level  = 0.01. Based on RMS2 net)
• Bootstrapped Networks (Bootstrapped with q = 5 models, and p = 0.85. Based on RMS3
net)
• Stochastic Variational Inference (BayesByBackprop with noise σ = 0.1)
• Expectation-Propagation (Alpha Divergences BB α-divergence with α = 0.1, noise σ = 0.1,
K = 10, prior var σ20 = 0.1.)
• RMS2 net (Learning rate decays, and it is reset every training period)
• RMS3 net (Learning rate decays, and it is not reset at all. Starts at γ = 1)
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